NAPI2B Low Patients Benefit From Targeted Therapy

NAPI2B low patients do they benefit at all? Well that's really what we're waiting to see on the final data so the initial data presented by Deb Richardson now gosh I guess that's about a year and a half old from SGO. You know we definitely saw patients with activity in the low expressors but the level of activity in the higher expressors was markedly improved again north of 40 percent. So again a potentially active agent like MIRV and those that don't have high expression but when we're really looking at particularly on a targeted therapy making sure we're identifying those patients who are going to have the highest opportunity for a positive efficacy and response.